# This SDS packet was issued with item:

078551947

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078551921 078551939



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 09/01/2022

 9.4
 10/19/2022
 52652-00025
 Date of first issue: 02/02/2015

#### **SECTION 1. IDENTIFICATION**

Product name : Ivermectin / Pyrantel Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

#### **SECTION 2. HAZARDS IDENTIFICATION**

# GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Combustible dust

**GHS** label elements

Signal Word : Warning

Hazard Statements : If small particles are generated during further processing,

handling or by other means, may form combustible dust

concentrations in air.

#### Other hazards

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

## **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
4,4'-Methylenebis[3-hydroxy-2-	22204-24-6	8.6
naphthoic] acid, compound with (E)-		
1,4,5,6-tetrahydro-1-methyl-2-[2-(2-		
thienyl)vinyl]pyrimidine (1:1)		
Propylene glycol	57-55-6	4.6
Ivermectin	70288-86-7	0.02

## **SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.



# **Ivermectin / Pyrantel Formulation**

Version **Revision Date:** SDS Number: Date of last issue: 09/01/2022 10/19/2022 52652-00025 Date of first issue: 02/02/2015 9.4

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

Wash with water and soap. In case of skin contact

Get medical attention if symptoms occur.

If in eyes, rinse well with water. In case of eye contact

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms

and effects, both acute and

delayed

Protection of first-aiders Notes to physician

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation. No special precautions are necessary for first aid responders.

Treat symptomatically and supportively.

#### **SECTION 5. FIRE-FIGHTING MEASURES**

Water spray Suitable extinguishing media

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical None known.

Unsuitable extinguishing

media

Specific hazards during fire

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx)

Sulfur oxides Metal oxides

Chlorine compounds

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

Evacuate area.

Special protective equipment :

for fire-fighters

Wear self-contained breathing apparatus for firefighting if

necessary.

Use personal protective equipment.

#### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protec- : tive equipment and emer-

gency procedures

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**Environmental precautions** Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 09/01/2022

 9.4
 10/19/2022
 52652-00025
 Date of first issue: 02/02/2015

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### **SECTION 7. HANDLING AND STORAGE**

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation Advice on safe handling Use only with adequate ventilation.

: Do not breathe dust.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

practice, based on the results of the workplace exposure

assessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

#### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)	22204-24-6	TWA	250 μg/m3 (OEB 2)	Internal
Propylene glycol	57-55-6	TWA	10 mg/m³	US WEEL



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 09/01/2022

 9.4
 10/19/2022
 52652-00025
 Date of first issue: 02/02/2015

Ivermectin	70288-86-7	TWA	30 μg/m3 (OEB 3)	Internal		
	Further information: Skin					
		Wipe limit	300 μg/100 cm2	Internal		

Engineering measures : All engineering controls should be implemented by facility

design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face

containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to

maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are

unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided

by air purifying respirators against exposure to any

hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other

circumstance where air purifying respirators may not provide

adequate protection.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

# **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**



# **Ivermectin / Pyrantel Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/01/2022 9.4 10/19/2022 52652-00025 Date of first issue: 02/02/2015

Appearance : powder

Color : brown

Odor : No data available

Odor Threshold : No data available

pH : 4 - 6 (68 °F / 20 °C)

(as aqueous solution)

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

log Pow: 3.22

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 09/01/2022

 9.4
 10/19/2022
 52652-00025
 Date of first issue: 02/02/2015

Molecular weight : No data available

Particle size : No data available

## **SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Oxidizing agents

Incompatible materials

Hazardous decomposition

No hazardous decomposition products are known.

products

#### **SECTION 11. TOXICOLOGICAL INFORMATION**

#### Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

#### **Acute toxicity**

Not classified based on available information.

**Product:** 

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg

Method: Calculation method

## **Components:**

4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Acute oral toxicity : LD50 (Rat): > 24,000 mg/kg

LD50 (Mouse): > 24,000 mg/kg

LD50 (Dog): 2,000 mg/kg

Propylene glycol:

Acute oral toxicity : LD50 (Rat): 22,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 44.9 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Assessment: The substance or mixture has no acute dermal



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 09/01/2022

 9.4
 10/19/2022
 52652-00025
 Date of first issue: 02/02/2015

toxicity

Ivermectin:

Acute oral toxicity : LD50 (Rat): 10 mg/kg

LD50 (Mouse): 25 mg/kg

LD50 (Monkey): > 24 mg/kg

Target Organs: Central nervous system Symptoms: Vomiting, Dilatation of the pupil Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5.11 mg/l

Exposure time: 1 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg

LD50 (Rat): > 660 mg/kg

#### Skin corrosion/irritation

Not classified based on available information.

#### **Components:**

Propylene glycol:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Ivermectin:

Species : Rabbit

Result : No skin irritation

#### Serious eye damage/eye irritation

Not classified based on available information.

#### **Components:**

Propylene glycol:

Species : Rabbit

Result : No eye irritation

Method : OECD Test Guideline 405

Ivermectin:

Species : Rabbit

Result : Mild eye irritation

#### Respiratory or skin sensitization

# Skin sensitization

Not classified based on available information.



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 09/01/2022

 9.4
 10/19/2022
 52652-00025
 Date of first issue: 02/02/2015

## Respiratory sensitization

Not classified based on available information.

#### **Components:**

Propylene glycol:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

Ivermectin:

Routes of exposure : Dermal Species : Humans

Result : Does not cause skin sensitization.

## Germ cell mutagenicity

Not classified based on available information.

#### Components:

4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Propylene glycol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Ivermectin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)
Test system: human diploid fibroblasts

Result: negative

Test Type: Mouse Lymphoma

Result: negative



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 09/01/2022

 9.4
 10/19/2022
 52652-00025
 Date of first issue: 02/02/2015

#### Carcinogenicity

Not classified based on available information.

#### **Components:**

## Propylene glycol:

Species: RatApplication Route: IngestionExposure time: 2 YearsResult: negative

#### Ivermectin:

Species : Rat Application Route : Oral

NOAEL : 1.5 mg/kg body weight

Result : negative

Remarks : Based on data from similar materials

Species : Mouse Application Route : Oral

NOAEL : 2.0 mg/kg body weight

Result : negative

Remarks : Based on data from similar materials

IARC No ingredient of this product present at levels greater than or equal to 0.1% is

identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA**No component of this product present at levels greater than or equal to 0.1% is

on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

#### Reproductive toxicity

Not classified based on available information.

#### Components:

# 4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 3,000 mg/kg body weight

Result: No effects on fertility and early embryonic

development were detected.

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 1,000 mg/kg body weight

Result: No effects on fertility and early embryonic

development were detected.



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 09/01/2022

 9.4
 10/19/2022
 52652-00025
 Date of first issue: 02/02/2015

Propylene glycol:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Mouse

Application Route: Ingestion

Result: negative

Effects on fetal development : Test Type: Embryo-fetal development

Species: Mouse

Application Route: Ingestion

Result: negative

Ivermectin:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 0.6 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Development

Species: Mouse

Application Route: Oral

Developmental Toxicity: NOAEL: 0.2 mg/kg body weight Result: Teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally

toxic doses

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 0.4 mg/kg body weight Result: Embryotoxic effects and adverse effects on the

offspring were detected.

Remarks: The mechanism or mode of action may not be rele-

vant in humans.

Test Type: Development

Species: Rabbit Application Route: Oral

Result: Teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally

toxic doses

#### STOT-single exposure

Not classified based on available information.

#### Components:

#### Ivermectin:

Target Organs : Central nervous system
Assessment : Causes damage to organs.

## STOT-repeated exposure

Not classified based on available information.



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 09/01/2022

 9.4
 10/19/2022
 52652-00025
 Date of first issue: 02/02/2015

#### Components:

Ivermectin:

Target Organs : Central nervous system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

#### Repeated dose toxicity

#### **Components:**

4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Species : Dog
NOAEL : 10 mg/kg
LOAEL : 30 mg/kg
Application Route : Ingestion
Exposure time : 3 d

Remarks : No significant adverse effects were reported

Species : Dog NOAEL : 600 mg/kg Application Route : Oral Exposure time : 19 d

Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 600 mg/kg
Application Route : Oral
Exposure time : 30 d

Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 600 mg/kg
Application Route : Oral
Exposure time : 90 d

Remarks : No significant adverse effects were reported

Propylene glycol:

Species : Rat, male

NOAEL : >= 1,700 mg/kg

Application Route : Ingestion

Exposure time : 2 y

Ivermectin:

Species : Dog
NOAEL : 0.5 mg/kg
LOAEL : 1 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Target Organs : Central nervous system

Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 09/01/2022

 9.4
 10/19/2022
 52652-00025
 Date of first issue: 02/02/2015

Species : Monkey
NOAEL : 1.2 mg/kg
Application Route : Oral
Exposure time : 2 Weeks

Remarks : No significant adverse effects were reported

Species : Rat

NOAEL : 0.4 mg/kg

LOAEL : 0.8 mg/kg

Application Route : Oral

Exposure time : 3 Months

Target Organs : spleen, Bone marrow, Kidney

**Aspiration toxicity** 

Not classified based on available information.

**Experience with human exposure** 

**Components:** 

4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Ingestion : Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhea,

Headache, Dizziness, Fever

Ivermectin:

Skin contact : Remarks: Can be absorbed through skin.

Eye contact : Remarks: May irritate eyes.

Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vom-

iting, anorexia, Lack of coordination

**SECTION 12. ECOLOGICAL INFORMATION** 

**Ecotoxicity** 

**Product:** 

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l

Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.000025 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1

mg/l Exposure time: 72 h

Laposule time. 72 ii

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 09/01/2022

 9.4
 10/19/2022
 52652-00025
 Date of first issue: 02/02/2015

#### Components:

4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

**Ecotoxicology Assessment** 

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

Propylene glycol:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 40,613 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Ceriodaphnia dubia (water flea)): 18,340 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

ErC50 (Skeletonema costatum (marine diatom)): 19,300 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Ceriodaphnia dubia (water flea)): 13,020 mg/l

Exposure time: 7 d

Toxicity to microorganisms : NOEC (Pseudomonas putida): > 20,000 mg/l

Exposure time: 18 h

Ivermectin:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l

Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.000025 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

#### Persistence and degradability

**Product:** 

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 50 % Exposure time: 240 d



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 09/01/2022

 9.4
 10/19/2022
 52652-00025
 Date of first issue: 02/02/2015

**Components:** 

Propylene glycol:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 98.3 % Exposure time: 28 d

Method: OECD Test Guideline 301F

Ivermectin:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 50 % Exposure time: 240 d

Bioaccumulative potential

**Product:** 

Bioaccumulation : Bioconcentration factor (BCF): 74

**Components:** 

Propylene glycol:

Partition coefficient: n- : log Pow: -1.07

octanol/water Method: Regulation (EC) No. 440/2008, Annex, A.8

Ivermectin:

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n-

octanol/water

: log Pow: 3.22

Mobility in soil
No data available

Other adverse effects

No data available

**SECTION 13. DISPOSAL CONSIDERATIONS** 

**Disposal methods** 

Waste from residues : Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

**SECTION 14. TRANSPORT INFORMATION** 

**International Regulations** 

**UNRTDG** 

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 09/01/2022

 9.4
 10/19/2022
 52652-00025
 Date of first issue: 02/02/2015

N.O.S.

(Ivermectin)

Class : 9
Packing group : III
Labels : 9

**IATA-DGR** 

UN/ID No. : UN 3077

Proper shipping name : Environmentally hazardous substance, solid, n.o.s.

(Ivermectin)

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo : 956

aircraft)

Packing instruction (passen- : 956

ger aircraft)

Environmentally hazardous : yes

**IMDG-Code** 

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Ivermectin)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

## Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### **Domestic regulation**

**49 CFR** 

UN/ID/NA number : UN 3077

Proper shipping name : Environmentally hazardous substance, solid, n.o.s.

(Ivermectin)

Class : 9
Packing group : III
Labels : CLASS 9
ERG Code : 171

Marine pollutant : yes(Ivermectin)

Remarks : Above applies only to containers over 119 gallons or 450

liters

Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

#### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 09/01/2022

 9.4
 10/19/2022
 52652-00025
 Date of first issue: 02/02/2015

#### **SECTION 15. REGULATORY INFORMATION**

#### **CERCLA Reportable Quantity**

Listed substances in the product are at low enough levels to not be expected to exceed the RQ

#### SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

#### SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Combustible dust

SARA 313 : This material does not contain any chemical components with

known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

#### **US State Regulations**

## Pennsylvania Right To Know

Soybean proteins 9010-10-0 4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound 22204-24-6

with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-

thienyl)vinyl]pyrimidine (1:1)

D(+)-Glucose monohydrate 5996-10-1 Propylene glycol 57-55-6 D-Glucono-1,5-lactone 90-80-2

## California Prop. 65

WARNING: This product can expose you to chemicals including tert-Butyl-4-methoxyphenol, which is/are known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.

#### The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### **SECTION 16. OTHER INFORMATION**

#### **Further information**




# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 09/01/2022

 9.4
 10/19/2022
 52652-00025
 Date of first issue: 02/02/2015

## NFPA 704:



Special hazard

#### HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

#### Full text of other abbreviations

US WEEL : USA. Workplace Environmental Exposure Levels (WEEL)

US WEEL / TWA : 8-hr TWA

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act



# **Ivermectin / Pyrantel Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 09/01/2022

 9.4
 10/19/2022
 52652-00025
 Date of first issue: 02/02/2015

(United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to

compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 10/19/2022

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8